Seroatlas · Human Serome Atlas

DECR2

Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]

Also known as: DECR2_HUMAN, PDCR, SDR17C1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NUI1
Gene: DECR2
Ensembl: ENSG00000242612
Chromosome: 16
Canonical length: 292 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Peroxisomes,Microtubules

OverviewNCBI Gene

Enables 2,4-dienoyl-CoA reductase (NADPH) activity and trans-2-enoyl-CoA reductase (NADPH) activity. Involved in unsaturated fatty acid biosynthetic process. Predicted to be located in cytosol and peroxisomal membrane. Predicted to be active in peroxisome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

292 residues, UniProt reviewed canonical sequence.

>Q9NUI1|DECR2
     1  MAQPPPDVEG DDCLPAYRHL FCPDLLRDKV AFITGGGSGI GFRIAEIFMR HGCHTVIASR
    61  SLPRVLTAAR KLAGATGRRC LPLSMDVRAP PAVMAAVDQA LKEFGRIDIL INCAAGNFLC
   121  PAGALSFNAF KTVMDIDTSG TFNVSRVLYE KFFRDHGGVI VNITATLGNR GQALQVHAGS
   181  AKAAVDAMTR HLAVEWGPQN IRVNSLAPGP ISGTEGLRRL GGPQASLSTK VTASPLQRLG
   241  NKTEIAHSVL YLASPLASYV TGAVLVADGG AWLTFPNGVK GLPDFASFSA KL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DECR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.25
Highest tissue expression: 174 nTPM

Expression across tissuesHPA

Tissue

liver: 174 nTPM
kidney: 39 nTPM
adrenal gland: 37 nTPM
skeletal muscle: 37 nTPM
pancreas: 23 nTPM
colon: 20 nTPM

Single-cell type

proximal tubule cells: 25 nCPM
tuft cells: 12 nCPM
astrocytes: 6.7 nCPM
bergmann glia: 6.3 nCPM
loop of henle epithelial cells: 5.2 nCPM
renal collecting duct intercalated cells: 4.6 nCPM

Immune cell

plasmacytoid DC: 7.9 nTPM
intermediate monocyte: 5.1 nTPM
myeloid DC: 5.1 nTPM
classical monocyte: 3.8 nTPM
NK-cell: 2.9 nTPM
gdT-cell: 2.8 nTPM

Brain region

hypothalamus: 4.8 nTPM
white matter: 3.5 nTPM
cerebral cortex: 3.2 nTPM
basal ganglia: 2.8 nTPM
hippocampal formation: 2.7 nTPM
medulla oblongata: 2.7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.68
gnomAD pLI: 0
gnomAD missense Z: -0.19
DepMap mean gene effect: 0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Short-chain dehydrogenase/reductase SDR
NAD(P)-binding domain superfamily
Ketoreductase domain
Enoyl-(Acyl carrier protein) reductase
Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DECR2 as an antibody target. Whether an autoantibody or antibody against DECR2 could matter depends on whether native DECR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DECR2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DECR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...